Subcutaneous sumatriptan compared with usual acute treatments for migraine : Clinical and pharmacoeconomic evaluation

Acta Neurologica Belgica

Volumn 98, Issue 4, 1998, Pages 332-341

  Laloux, Patrice ^c   Vakaet, A ^a   Monseu, G ^d   Jacquy, J ^d   Bourgeois, Ph ^b   Van Der Linden, Ch ^d  

^a AZ Maria Middelares   (Belgium)

^b Heilig Hart Ziekenhuis   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d NONE

Author keywords

Migraine; Pharmacoeconomics; Quality of life; Sumatriptan; Treatment

Indexed keywords

SUMATRIPTAN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; QUALITY OF LIFE; RESOURCE ALLOCATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032414168     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Répertoire commenté des médicaments. 1994. Bruxelles, Centre belge d'information pharmacothérapeutique.
2. ADELMAN J. U., SHARFMAN M., JOHNSON R. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medications in nurses with migraine. Am. J. Man. Care, 1996, 2 : 1407-1416.
3. ADELMAN J. U., VON SEGGERN R. Cost considerations in headache treatment. Part 1 : Prophylactic migraine treatment. Headache, 1995, 35 : 479-487.
4. BOUCHARD J., CORTELLI P., DAHLÖF C., HEYWOOD J., JANSEN J. P. et al. A multinational investigation of the impact of subcutaneous sumatriptan. IV. Patient satisfaction. Pharmacoeconomics, 1997, 11 : 43-50.
5. BOUREAU F., CHAZOT G., EMILE J., BERTIN L., D'ALLENS H. et al. Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. Eur. Neurol., 1995, 35 : 264-269.
6. BROWN E. G., ENDERSBY C. A., SMITH R. N., TALBOT J. C. C. The safety and tolerability of sumatriptan : An overview. Eur. Neurol., 1991, 31 : 339-344.
7. CADY R. K., WENDT J. K., KIRCHNER J. R., SARGENT J. D., ROTHROCK J. F. et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA, 1991, 265 : 2831-2835.
8. CAVALLINI A., MICIELI G., BUSSONE G., ROSSI F., NAPPI G. Headache and quality of life. Headache, 1995, 35 : 29-35.
9. CLARKE C. E., MACMILLAN L., SONDHI S., WELLS N. E. J. Economic and social impact of migraine. Qjm. Mon. J. Assoc. Phys., 1996, 89 : 77-84.
10. CLOUSE J. C., OSTERHAUS J. T. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann. Pharmacother., 1994, 28 : 659-664.
11. COHEN J. A., BEALL D. G., MILLER D. W., BECK A., PAIT G. et al. Subcutaneous sumatriptan for the treatment of migraine : Humanistic, economic, and clinical consequences. Fam. Med., 1996, 28 : 171-177.
12. CORTELLI P., DAHLÖF C., BOUCHARD J., HEYWOOD J., JANSEN J. P. et al. A multinational investigation of the impact of subcutaneous sumatriptan. III. Workplace productivity and non-workplace activity. Pharmacoeconomics, 1997, 11 : 35-42.
13. COUKELL A. J., LAMB H. M. Sumatriptan : A pharmacoeconomic review of its use in migraine. Pharmacoeconomics, 1997, 11 : 473-490.
14. CULL R. A., WELLS N. E. J., MIOCEVICH M. L. The economic cost of migraine. Br. J. Med. Econ., 1992, 2 : 103-115.
15. DAHLÖF C. Assessment of health-related quality of life in migraine. Cephalalgia, 1993, 13 : 233-237.
16. DAHLÖF C., BOUCHARD J., CORTELLI P., HEYWOOD J., JANSEN J. P. et al. A multinational investigation of the impact of subcutaneous sumatriptan. II. Health-related quality of life. Pharmacoeconomics, 1997, 11 : 24-34.
17. DAHLÖF C. G. H. How does sumatriptan perform in clinical practice ? Cephalalgia, 1995, 15 : 21-28.
18. DAVEY P. J., LEEDER S. R. The cost of migraine : More than just a headache ? Pharmacoeconomics, 1992, 2 : 5-7.
19. DE LISSOVOY G., LAZARUS S. S. The economic cost of migraine. Present state of knowledge. Neurology, 1994, 44 : S56-S62.
20. DRUMMOND M. Cost-of-illness studies : A major headache ? Pharmacoeconomics, 1992, 2 : 1-4.
21. FERRARI M. D. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N. Engl. J. Med., 1991, 325 : 316-321.
22. GREEN J. E. Migraine abroad : a survey of migraine in England 1975-1976. Headache, 1977, 17 : 67-68.
23. GREINER D. L., ADDY S. N. Sumatriptan use in a large group-model health maintenance organization. Am. J. Health Syst. Pharm., 1996, 53 : 633-638.
24. GROSS M. L. P., DOWSON A. J., DEAVY L., DUTHIE T. Impact of oral sumatriptan 50 mg on work productivity and quality of life in migraineurs. Br. J. Med. Econ., 1996, 10 : 231-246.
25. GROSS M. L. P., KAY J., TURNER A. M., JEWSBURY J., CLEAL A. L. Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Headache, 1995, 35 : 601-606.
26. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia, 1988, 8 : 1-96.
27. HENRY P., MICHEL P., BROCHET B., DARTIGUES J. F., TISON S. et al. A nationwide survey of migraine in France : Prevalence and clinical features in adults. Cephalalgia, 1997, 12 : 229-237.
28. HEYWOOD J., BOUCHARD J., CORTELLI P., DAHLÖF C., JANSEN J. P. et al. A multinational investigation of the impact of subcutaneous sumatriptan : Design, methods and clinical findings. Pharmacoeconomics, 1997, 11 : 11-23.
29. JHINGRAN P., CADY R. K., RUBINO J., MILLER D., GRICE R. B. et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J. Fam. Pract., 1996, 42 : 36-42.
30. KOZMA C. M., MAUCH R. P., REEDER C. E., LAWRENCE B. J. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. Clin. Ther., 1994, 16 : 1037-1051.
31. KRYST S., SCHERL E. A population-based survey of the social and personal impact of headache. Headache, 1994, 34 : 344-350.
32. LEGG R. F., SCLAR D. A., NEMEC D. L., TARNAI J., MACKOWIAK J. I. Cost benefit of sumatriptan to an employer. J. Occup. Environ. Med., 1997, 39 : 652-657.
33. LIPTON R. B., STEWART W. F., VON KORFF M. The burden of migraine. A review of cost to society. Pharmacoeconomics, 1994, 6 : 215-221.
34. LIPTON R. B., STEWART W. F., VON KORFF M. Migraine impact and functional disability. Cephalalgia, 1995, 15 : 4-9.
35. LITAKER D. G., SOLOMON G. D., GENZEN J. R. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache, 1996, 36 : 538-541.
36. MERIKANGAS K. R., WHITAKER A. E., ISLER H., ANGST J. The Zurich study : XXIII - Epidemiology of headache syndromes in the Zurich cohort study of young adults. Eur. Arch. Psychiatry Clin. Neurosci., 1994, 244 : 145-152.
37. MICHEL P., DARTIGUES J. F., LINDOULSI A., HENRY P. Loss of productivity and quality of life in migraine sufferers among French workers : Results from the GAZEL cohort. Headache, 1997, 37 : 71-78.
38. MILLER D. W., MARTIN B. C., LOO C. M. Sumatriptan and lost productivity time : a time series analysis of diary data. Clin. Ther., 1996, 18 : 1263-1275.
39. MUSHET G. R., MILLER D., CLEMENTS B., PAIT G., GUTTERMAN D. L. Impact of sumatriptan on workplace productivity, non work activities, and health-related quality of life among hospital employees with migraine. Headache, 1996, 36 : 137-143.
40. OSTERHAUS J. T., GUTTERMAN D. L., PLACHETKO J. R. Healthcare resource use and labour costs of migraine headache in the United States. Pharmacoeconomics, 1992, 2 : 67-76.
41. PAYNE K., KOZMA C. M., LAWRENCE B. J. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine : A retrospective cost-efficacy analysis. Pharmacoeconomics, 1996, 10 : 59-71.
42. PLOSKER G. L., MCTAVISH D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs, 1994, 47 : 622-651.
43. RAMADAN N. M., SCHULTZ L. L., GILKEY S. J. Migraine prophylactic drugs : Proof of efficacy, utilization and cost. Cephalalgia, 1997, 17 : 73-80.
44. RAPOPORT A. M. Recurrent migraine : cost-effective care. Neurology, 1994, 44 : S25-S28.
45. RASMUSSEN B. K., JENSEN R., OLESEN J. Questionnaire versus clinical interview in the diagnosis of headache. Headache, 1991a, 31 : 290-295.
46. RASMUSSEN B. K., JENSEN R., SCHOLL M. et al. Epidemiology of headache in a general population : A prevalence study. J. Clin. Epidemiol., 1991b, 44 : 1147-1157.
47. RICHARD A., HENRY P., CHAZOT G., MASSIOU H., TISON S. et al. Quality of life and migraine : validation of QVM questionnaire. Therapie, 1993, 48 : 89-96.
48. SCHOENEN J. Epidémiologie et impact de la migraine. Cahiers de Médecine du Travail, 1995, 32 : 203-205.
49. SCHOENEN J., BULCKE J., CAEKEBEKE J., DEHAEME I., DE KEYSER J. et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device : comparison with customary treatment in an open, longitudinal study. Cephalalgia, 1994, 14 : 55-63.
50. SCHOENEN J., CAEKEBEKE J., LOUIS P. and PIERRE P. A questionnaire-based survey of migraine in the Belgian population : prevalence, demography, socio-economic factors. 4th International Headache Research Seminar : headache classification and epidemiology, 1993. Copenhagen.
51. SCHWARTZ B. S., STEWART W. F., LIPTON R. B. Lost workdays and decreased work effectiveness associated with headache in workplace. J. Occup. Environ. Med., 1997, 39 : 320-327.
52. SOLOMON G. D., PRICE K. L. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics, 1997, 11 : 1-10.
53. SOLOMON G. D., SKOBIERANDA F. G., GENZEN J. R. Quality of life assessment among migraine patients treated with sumatriptan. Headache, 1995, 35 : 449-454.
54. STANG P. E., OSTERHAUS J. T. Impact of migraine in the United States : Data from the National Health Interview Survey. Headache, 1993, 33 : 29-35.
55. STEINER T. J. Long-term cost-benefit assessment of anti-migraine drugs. Cephalalgia, 1995, 15 : 37-40.
56. STEWART W. F., LIPTON R. B. The economic and social impact of migraine. Eur. Neurol., 1994, 34 : 12-17.
57. STEWART W. F., LIPTON R. B., CELENTANO D. D., REED M. L. Prevalence of migraine headache in the United States : Relation to age, income, race, and other sociodemographic factors. JAMA, 1992, 267 : 64-69.
58. STEWART W. F., LIPTON R. B., SIMON D. Work-related disability : Results from the American migraine study. Cephalalgia, 1996, 16 : 231-238.
59. TFELT HANSEN P., HENRY P., MULDER L. J., SCHELDEWAERT R. G., SCHOENEN J. et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet, 1995, 346 : 923-926.
60. TO T, WU K. Health care utilization and disability of migraine : The Ontario health survey. Can. J. Public Health, 1995, 86 : 195-199.
61. VAN ROIJEN L., ESSINK BOT M., KOOPMANSCHAP M. A., MICHEL B. C., RUTTEN F. H. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics, 1995, 7 : 170-179.